# Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus

> **NCT02713477** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 20 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010
- **DRUG:** Insulin glargine HOE901
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02713477
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02713477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02713477, "Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02713477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*